Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drug Ad Warning Letters Total Four In September; J&J Cited Three Times

Executive Summary

FDA's drug ad division posted four warning letters to its website in the second half of September, three for Johnson & Johnson ads

You may also be interested in...



J&J, Abbott Give Strong Start To Earnings Season; Pfizer Weathers Neurontin

J&J and Abbott kicked off the third quarter earnings season for drug companies on a strong note

J&J, Abbott Give Strong Start To Earnings Season; Pfizer Weathers Neurontin

J&J and Abbott kicked off the third quarter earnings season for drug companies on a strong note

Topamax Draws FDA Warning Letter For Promoting Unsafe Use In Children

FDA is citing Johnson & Johnson's Topamax for a website and sales aid that lack sufficient safety information

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel